kiny
Well-known member
- Joined
- Apr 28, 2011
- Messages
- 3,463
Defective acute inflammation in Crohn’s disease: a clinical investigation
Linking it because it's hard to wrap your head around crohn being an immunodeficiency, this is the earliest study I have read and started to realise there are immunodeficiencies in crohn, the whole disease is related to immunodeficiencies. Especially autophagy and the primary inflammatory response is completely compromised in crohn's disease patients, if relevant the hygiene theory would further compromise the acquired immune response leading to more immunodeficiencies.
Patients with crohn's disease, not on immunosupressive drugs, with an optimal nutritional status.
Against controls, with similar age, nutritional status, without crohn's disease.
They did a biopsy on them, and they checked the inflammatory response and healing. People with crohn's disease had lowered neutrophil response and took longer to heal.
They wondered if this immunodeficiency was localised in the gut or everywhere. So they infected the arm of people (with a small slit) with prepared bacteria (E coli type) and checked what happened.
People with crohn's disease had again, a weaker innate immune response, took longer to clear the bacteria and longer to heal.
Those recent studies that showed death rates for crohn's disease have not gone down in decades, partly because of the big number of infections people with crohn's disease are getting, because of the immunosupressive drugs, the clinical environment they are in, and their genetic and acquired immunodeficiencies (genes, hygiene theory).
If the top-down approach was used everywhere, deaths for crohn's disease would have likely been higher in the last decades than before, long-term use of immunosupressive drugs carries huge risks when given to an immunodeficient person who is constantly in a hazardous medical environment.
Some of the drugs that were approved for crohn's disease were approved on the condition that they would lower deaths related to crohn's disease. Evidence has shown this is not the case, since deaths are not going down.
Some GI should really start thinking what they are doing with a disease that is spreading worldwide, how ignoring evidence is hurting people with crohn's disease, and how current treatment with immunosupressive drugs is not a solution for crohn's disease and never will be.
You can not walk the road of veduzolimab (and all the trials before where you killed people) and interleukin blockers and keep endangering the lives of people with crohn's disease. The constant revenue stream of immunosupressive drugs not only makes GI liable when they put profits in front of patient care, they endanger the lives of people.
The evidence is there, if you take profits over care, someone will one day show how you ignored evidence in favor of profits and they'll tell you, you were liable.
I 100% agree with the German paper that veto'd veduzolimab and interleukin blockers. You better have the best lawyer in town when a person on veduzolimab gets a brain infection, since many many people have warned you.
Linking it because it's hard to wrap your head around crohn being an immunodeficiency, this is the earliest study I have read and started to realise there are immunodeficiencies in crohn, the whole disease is related to immunodeficiencies. Especially autophagy and the primary inflammatory response is completely compromised in crohn's disease patients, if relevant the hygiene theory would further compromise the acquired immune response leading to more immunodeficiencies.
Patients with crohn's disease, not on immunosupressive drugs, with an optimal nutritional status.
Against controls, with similar age, nutritional status, without crohn's disease.
They did a biopsy on them, and they checked the inflammatory response and healing. People with crohn's disease had lowered neutrophil response and took longer to heal.
They wondered if this immunodeficiency was localised in the gut or everywhere. So they infected the arm of people (with a small slit) with prepared bacteria (E coli type) and checked what happened.
People with crohn's disease had again, a weaker innate immune response, took longer to clear the bacteria and longer to heal.
Those recent studies that showed death rates for crohn's disease have not gone down in decades, partly because of the big number of infections people with crohn's disease are getting, because of the immunosupressive drugs, the clinical environment they are in, and their genetic and acquired immunodeficiencies (genes, hygiene theory).
If the top-down approach was used everywhere, deaths for crohn's disease would have likely been higher in the last decades than before, long-term use of immunosupressive drugs carries huge risks when given to an immunodeficient person who is constantly in a hazardous medical environment.
Some of the drugs that were approved for crohn's disease were approved on the condition that they would lower deaths related to crohn's disease. Evidence has shown this is not the case, since deaths are not going down.
Some GI should really start thinking what they are doing with a disease that is spreading worldwide, how ignoring evidence is hurting people with crohn's disease, and how current treatment with immunosupressive drugs is not a solution for crohn's disease and never will be.
You can not walk the road of veduzolimab (and all the trials before where you killed people) and interleukin blockers and keep endangering the lives of people with crohn's disease. The constant revenue stream of immunosupressive drugs not only makes GI liable when they put profits in front of patient care, they endanger the lives of people.
The evidence is there, if you take profits over care, someone will one day show how you ignored evidence in favor of profits and they'll tell you, you were liable.
I 100% agree with the German paper that veto'd veduzolimab and interleukin blockers. You better have the best lawyer in town when a person on veduzolimab gets a brain infection, since many many people have warned you.
Last edited: